Elevated Fibrinogen with Prolonged Prothrombin Time

Primary Interpretation Framework

Fibrinogen elevation is consistent with an inflammatory response, as fibrinogen functions as an acute phase reactant that increases during infection, inflammation, malignancy, or tissue injury, according to the International Anesthesia Research Society 1, 2, 3.
In COVID-19 coagulopathy, elevated fibrinogen reflects the inflammatory state rather than indicating reduced thrombotic risk, as stated by the International Society on Thrombosis and Haemostasis 2, 3.
Fibrinogen levels have not been associated with thrombotic risk prediction in most studies and cannot be used to identify patients at risk for thrombosis, as reported by the American Society of Anesthesiologists 1.

Despite the prolonged PT, elevated fibrinogen is associated with increased thrombotic risk, not bleeding risk, and the PT prolongation must reach ≥1.5 times the mean normal value to correlate with increased clinical bleeding risk, according to the British Journal of Anaesthesia 9.
Fibrinogen <1.0 g/L indicates critical bleeding risk and typically occurs after significant blood loss in acute hemorrhage, as stated by the British Journal of Anaesthesia 9.
Fibrinogen <2.0 g/L warrants hospital admission and close monitoring in acute illness, as recommended by the Society of Critical Care Medicine 7.

Complete blood count with platelet count is recommended as an immediate laboratory test, as stated by the International Society on Thrombosis and Haemostasis 5, 7.
D-dimer level is recommended as an immediate laboratory test to assess for disseminated intravascular coagulation (DIC), as stated by the Society of Critical Care Medicine 6, 7.
Fibrinogen trend (repeat measurement) is recommended to assess for changes in fibrinogen levels over time, as stated by the International Anesthesia Research Society 1.

Elevated fibrinogen with prolonged PT may represent the hyperinflammatory phase in acute illness or COVID-19, where thrombotic risk predominates over bleeding risk, as stated by the International Anesthesia Research Society 1, 2.
Thrombotic events typically occur 7.0 days after admission, while hemorrhagic events occur 11.4 days after admission in acute illness or COVID-19, as reported by the International Anesthesia Research Society 1.
Normal fibrinogen in third trimester ranges from 3.7-6.2 g/L, making elevated fibrinogen potentially normal in pregnancy, as stated by the International Society on Thrombosis and Haemostasis 2, 3.

Do NOT empirically correct the PT with fresh frozen plasma or prothrombin complex concentrates unless there is active bleeding or urgent surgery planned, as the elevated fibrinogen suggests preserved hemostatic capacity, as recommended by the European Association for the Study of the Liver 8, 9.
Monitor for thrombotic complications given the elevated fibrinogen, particularly if D-dimer is also elevated, as stated by the Society of Critical Care Medicine 6, 7.
Consider thromboprophylaxis based on overall clinical context and thrombotic risk assessment, not based on the prolonged PT alone, as recommended by the American College of Chest Physicians 1, 6.